BioCentury
ARTICLE | Company News

UCB re-partners Cimzia in Japan with Astellas

February 2, 2012 1:42 AM UTC

UCB Group (Euronext:UCB) partnered with Astellas Pharma Inc. (Tokyo:4503) to co-develop and co-commercialize UCB's anti-TNF therapy Cimzia certolizumab pegol in Japan. The new deal follows last month's announcement that UCB and Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) stopped co-development of Cimza in Japan after terminating the immunology portion of a 2008 partnership (see BioCentury Extra, Jan. 13). ...